ESC 2026 marked a turning point — GLP-1s earn their first formal heart failure guideline recommendation and become a cardiometabolic platform.
Feature|Articles|September 22, 2026
The Most Expensive CI Failure is Missing the Moment Your Strategic Assumption Became Wrong
Author(s)Rafaat Rahmani
The best CI partner isn't the one with the most data — it's the one willing to tell you your assumptions are wrong.
Advertisement
Advertisement
Pharma companies are heading into another competitive intelligence (CI) request for proposal (RFP) season as they finalize 2027 budgets and reassess their external partners. At the same time, CI leaders are being asked to do more with increasingly sophisticated technology and overwhelming amounts of data, often while working with fewer external CI vendors.
Related to this article
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
How the proposed lateral network can change the traditional mindset around communications and pharma’s role in today’s new flow of health information.
Advertisement
Advertisement